Similar articles

• Re: Screening and Monitoring in Men Prescribed Testosterone Therapy in the U.S., 2001-2010.

  Seftel AD. Seftel AD. J Urol. 2015 Sep;194(3):761. doi: 10.1016/j.juro.2015.06.060. Epub 2015 Jun 18. J Urol. 2015. PMID: 26292884 No abstract available.
• Screening and monitoring in men prescribed testosterone therapy in the U.S., 2001-2010.

  Baillargeon J, Urban RJ, Kuo YF, Holmes HM, Raji MA, Morgentaler A, Howrey BT, Lin YL, Ottenbacher KJ. Baillargeon J, et al. Public Health Rep. 2015 Mar-Apr;130(2):143-52. doi: 10.1177/003335491513000207. Public Health Rep. 2015. PMID: 25729103 Free PMC article.
• Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.

  Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Khera M, et al. J Urol. 2011 Sep;186(3):1005-11. doi: 10.1016/j.juro.2011.04.065. Epub 2011 Jul 23. J Urol. 2011. PMID: 21788049
• Risks of testosterone-replacement therapy and recommendations for monitoring.

  Rhoden EL, Morgentaler A. Rhoden EL, et al. N Engl J Med. 2004 Jan 29;350(5):482-92. doi: 10.1056/NEJMra022251. N Engl J Med. 2004. PMID: 14749457 Review. No abstract available.
• Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan.

  Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Bhasin S, et al. J Androl. 2003 May-Jun;24(3):299-311. doi: 10.1002/j.1939-4640.2003.tb02676.x. J Androl. 2003. PMID: 12721204 Review. No abstract available.